Long COVID
Also known as: Chronic COVID, Long-haul COVID, Long-term effects of COVID, Post-COVID Conditions, Post-acute COVID-19
Methodology & AI Transparency ⓘ
Long COVID Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is long COVID? COVID-19 (coronavirus disease 2019) is an illness caused by a virus.
- 2 Real-world patient consensus: Synonyms for Long COVID (B37.0): Chronic COVID, Long-haul COVID, Long-term effects of COVID (Infections & Antivirals).
- 3 Typical cash cost range: Primary evaluation for Long COVID incorporates sepsis/severity red-flag triage [Long COVID B37.0] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Long COVID: maintaining C-Reactive Protein / in Long COVID (B37.0: Procalcitonin) within Resolution to baseline (B37.0).
Ask our AI Specialists anything about Long COVID
What Is Long COVID?
What is long COVID? COVID-19 (coronavirus disease 2019) is an illness caused by a virus. Many people get better within a few days or weeks after being infected with the virus. But if you have symptoms that last for at least three months or more, you may have long COVID. Long COVID is a chronic (long-lasting) condition. It includes a wide range of symptoms or conditions that can range from mild to severe. You may: Have symptoms that linger for weeks, months, or even years Seem to recover from COVID-19 but then see your symptoms return Develop new symptoms or new health conditions within a few months of having COVID-19 There are several other names for long COVID.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Long COVID (code B37.0) is microbial (bacterial [Long COVID B37.0], Cross-referenced with NIH MeSH (Post-Acute COVID-19 Syndrome, COVID-19), which Bacterial, Viral & Fungal Infections clinicians address while surveilling C-Reactive Protein / in Long COVID (B37.0: Procalcitonin) (Resolution to baseline (B37.0)).
Common Symptoms & Clinical Signs
- • Have symptoms that linger for weeks, months, or even years
- • Seem to recover from COVID-19 but then see your symptoms return
- • Presentation of Long COVID (B37.0): acute fever, chills, in Long COVID (B37.0: malaise, and myalgias)
- • Secondary Long COVID clinical sign: sore throat, productive in Long COVID (B37.0: cough, sinus/ear pain,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Long COVID Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Long COVID (B37.0: Procalcitonin) | Resolution to baseline (B37.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Long COVID (B37.0: Culture & Sensitivity) | Pathogen clearance / negative test (B37.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Long COVID (B37.0: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Long COVID
Treatment selection for Long COVID depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Long COVID)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Heart and blood vessel and Kidney Outcomes and Mortality With Long-Acting: What a 71,351-Participant Study Found As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D. Diabetes care • 2025-05-01 • Meta-Analysis | N = 71,351 | 99/100 | PMID 40156846 ↗ |
| New Insights on Long-Term heart and blood vessel Safety of Testosterone-Replacement Therapy in: What a 9,280-Participant Study Found In men with low to low-normal testosterone, aged 40 and above, TRT did not increase all-cause mortality, heart and blood vessel mortality, stroke, or heart attack, but increased the incidence of cardiac arrhythmias. American journal of cardiovascular drugs : drugs, devices, and other interventions • 2025-11-15 • Meta-Analysis | N = 9,280 | 99/100 | PMID 40694252 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal: What a 16,071-Participant Study Found These results. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2021-07-15 • Phase III Randomized Trial | N = 16,071 | 96/100 | PMID 33724542 ↗ |
| New Insights on Long-term real-world benefits and safety of ixekizumab: A 5-year analysis of the: What a 1,346-Participant Study Found IXE demonstrates sustained efficacy and consistent safety through 264 weeks in patients using the approved dose. Journal of the American Academy of Dermatology • 2021-08-15 • Phase III Randomized Trial | N = 1,346 | 96/100 | PMID 33253833 ↗ |
Long COVID Patient Community & “People Like Me” Threads
Filter Long COVID community threads and patient logs by age, biological sex, dosage, and treatment duration.